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To investigate the occurrence of somatic mitochondrial DNA (mtDNA) mutations in human primary endometrial carcinomas, we
sequenced the D-loop region, the 12S and 16S rRNA genes of mtDNA of cancer tissues and their matched normal controls. About
56% (28 out of 50) of cases carry one or more somatic changes in mtDNA including deletion, point mutation and mitochondrial
microsatellite instability (mtMSI), namely the change in length of short base-repetitive sequences of mtDNA. In particular, mtMSI was
frequently detected in 89% (25 out of 28) of all the cases carrying somatic changes followed by point mutations (25%; seven out of
28) and deletion (3.5%; one out of 28). The CCCCCTCCCC sequences located in the Hypervariable Regions I and II of the D-loop
and 12S rRNA gene are instability hot spot regions in endometrial carcinomas. It is suggested that errors in replication may account
for the high frequency of mtMSI in human endometrial carcinomas. The relatively high prevalence of mtMSI may be a potential new
tool for detection of endometrial cancer.
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The occurrence of somatic mitochondrial DNA (mtDNA) muta-
tions in various human cancers has recently been reported (Polyak
et al, 1998; Fliss et al, 2000; Jeronimo et al, 2001; Jones et al, 2001;
Kirches et al, 2001; Liu et al, 2001; Maximo et al, 2001; Parrella
et al, 2001). The genetic changes include deletions, point mutations
and mitochondrial microsatellite instability (mtMSI), defined as
the change in length in short base-repetitive sequences of mtDNA.
Most of the mtDNA mutations were point mutations involving T-
Co rG -A transitions, probably induced by oxidative stress. In
contrast, DNA deletions and mtMSI, which might be generated
during erroneous replication, occurred sporadically.
This D-loop region is often selected for study in view of its
tendency to accumulate mutations more rapidly than other regions
of mtDNA. In our previous study, we sequenced the D-loop region
(nucleotide position (np) 16024–576) of 15 pairs of ovarian
tumour and matched normal samples and found a total of nine
somatic mutations in three samples (20%; three out of 15) (Liu
et al, 2001). In addition, in the same study, we completely
sequenced the mitochondrial genomes of 10 ovarian tumour
samples and found six somatic mutations, respectively, in six
samples (60%; six out of 10) (Liu et al, 2001). Four point mutations
and one mtMSI out of the six mutations were detected in the
region containing the D-loop, 12S and 16S rRNA genes. Indeed,
consistent with other studies, the majority of the mtDNA
mutations have been found in the D-loop and the adjacent genes
in several tumours (Fliss et al, 2000).
So far, the role of mtDNA in endometrial carcinomas has not
been reported. To further our investigation on the occurrence of
mtDNA mutations in human cancers, we selectively (based on our
previous results) sequenced the D-loop, the 12S and 16S rRNA
genes (spanning from np 16024–3229) of mtDNA of endometrial
carcinomas.
MATERIALS AND METHODS
Fifty frozen samples of primary endometrial carcinomas and those
of their matched normal tissues (including cervix and/or
lymphocytes) obtained after surgery were retrieved without
specific selection from our tissue bank and used for DNA analysis
in this study (approved (No.: EC 1517-00) by the Ethics Committee
of the University of Hong Kong). In addition, pathologic paraffin-
embedded tumour tissues and sera (if available) from the same set
of individuals were also used to cross-check the DNA changes
found. DNA was extracted from frozen tissues, paraffin-embedded
tumour tissues and sera by the methods described previously (Liu
et al, 2001). The segment of mtDNA encompassing the D-loop, 12S
and 16S rRNA genes was amplified from tissue extracts by long-
range and high-fidelity PCR amplification system under conditions
as recommended by the manufacturer (Roche Diagnostics GmbH,
Mannheim, Germany). Sequencing of the PCR products was
carried out using the same procedure as we used in our previous
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sstudy of mtDNA mutations in ovarian carcinomas (Liu et al, 2001).
DNA sequences were analysed using Dnasis software. In addition,
electropherograms were read manually to identify mutant
sequence present at a low level. From our experience, an mtDNA
sequence constituting as low as 15% in a heteroplasmic sample
(containing a mixture of mtDNA sequences) can be detectable by
DNA sequencing. To confirm the DNA changes found in frozen
tissues, the corresponding mtDNA fragments within DNA
extracted from paraffin-embedded tissues and serum from the
corresponding individuals were also analysed. Although paraffin-
embedded DNA may undergo some degradation after chemical
treatment for fixation, the high copy number of mitochondrial
genomes per cell makes PCR amplification of short mtDNA
fragments readily achievable, yielding reproducible data. Details of
PCR primers and sequencing primers are available upon request
from the authors.
RESULTS AND DISCUSSION
Fifty samples of primary endometrial carcinomas and their
matched normal controls were studied to determine whether
mtDNA mutations could be identified. Indeed, 56% (28 out of 50)
of the endometrial tumours were found to carry one or more
somatic mtDNA mutations including deletions, point mutations
and mtMSI (Figure 1; Table 1). Somatic mtDNA mutations are
defined as those present in the tumour but not in the normal tissue
from the patient concerned. The revised Cambridge sequence (wild
type) of the relevant position, in each case, is shown for reference
in Table 1. The mtDNA in normal tissue of individual patients
constitutes the mitochondrial haplotype but may differ from
this reference sequence, thereby representing a germline poly-
morphism.
In just one (U9; Table 1) of the 50 tumour samples, a
homoplasmic mtDNA deletion involving a pair of 9-bp direct
repeats (CCAAACCCC) located at np 298–306 and np 348–356
was detected in the D-loop. The mtDNA mutation deleted 50-bp of
DNA sequence including the Conserved Sequence Block (CSB) II
starting at np 298 with one of the direct repeats retained.
In addition, a total of seven somatic point mutations (14%;
seven out of 50) were detected in the current set of endometrial
tumour samples (Table 1). Three different mutations were detected
in the D-loop, one in each of the samples G12, U34 and U10.
Another three mutations were detected in the 12S rRNA gene (in
U27, U59 and G29) and a further one in the 16S rRNA gene (in
U44). They were all novel mtDNA mutations except the one at np
152 of G12 (Liu et al, 2001). The mutations were all either T-Co r
G-A transitions.
Other than deletion and point mutations, a high frequency
(50%; 25 out of 50) of mtMSI was detected, especially in the D-loop
region in these 50 endometrial tumour samples. We observed
mtMSI in four different regions (Table 1), including CA repeats at
np 514–523 within a nonfunctional D-loop sequence and a
common homopolymeric C stretch interrupted by a T
(CCCCCTCCCC) at each of the following locations: np 956–965
within the 12S rRNA gene; np 303–315 within the CSB II; and np
16184–16193 at the 30 end of the termination-associated sequence.
The sequencing details illustrating two different features of the
occurrence of mtMSI are depicted in Figure 2. The normal DNA of
sample U111 (Figure 2A) is homoplasmic containing a consecutive
set of four CA dinucleotides starting from np 514. In the tumour,
the sequence has expanded to five CA dinucleotides. This CA-
repeat instability was only found in U111 (2%; one out of 50)
(Table 1). A more complex example of mtMSI is shown in
Figure 2B. The normal DNA of sample U109 is heteroplasmic. It
contains stretches of cytosine residues of different lengths starting
from np 303 (C8, C9 and C10 are in similar proportions but C11 is
a minority species). In the tumour, the relative predominance of
these length variants has shifted markedly, the mtDNA sequence
now containing mainly C8 and a small proportion of C9. The use of
DNA sequencing to detect mtMSI allows us to determine exactly
the somatic changes and to estimate the relative proportion of each
type of sequence within a heteroplasmic sample.
Novel mtMSI located within the 12S rRNA gene (Table 1) was
found in the present study. The changes were either the deletion/
insertion of one cytosine residue at the homopolymorphic C tract
in front of the thymine (detected in U24; U32; U120) or the
germline T-C polymorphism producing an extra long homo-
polymorphic C tract leading to DNA instability (detected in U27).
The frequency of occurrence was 8% (four out of 50).
We observed mtMSI in two other regions in the D-loop. Changes
in length of the homopolymorphic cytosine at np 303–309 were
detected in 32% (16 out of 50) of endometrial carcinoma samples.
Another mtMSI involves the CCCCCTCCCC sequence at np
16184–16193 at the 30 end of the termination-associated sequence
and within the 7S DNA binding site. The germline T-C
polymorphism at np 16189 produced an uninterrupted C tract
that was unstable in the tumour (Table 1). The frequency of
occurrence was 14% (seven out of 50).
The mtMSI within the mononucleotide repeat at np 303–309 is
frequently observed in endometrial tumour samples (32%; 16 out
of 50). This mtMSI was also detected in ovarian carcinomas (Liu
et al, 2001) and other human tumours (Sanchez-Cespedes et al,
2001) with an average frequency of 22% (55 out of 247). In
concordance with the data of Sanchez-Cespedes et al (2001),
patients carrying mtDNA instability at this particular region had
higher levels of heteroplasmic length variants in the normal tissues
than patients not showing instability. Heteroplasmic length
variants of this region were found to be quite constant during
life (Lagerstrom-Fermer et al, 2001). This region is part of the CSB
II and the binding site of replication primer. It is not clear if the
relatively unstable somatic changes would alter mtDNA replication
in the tumour cell.
The germline T-C polymorphism at np 16189 producing an
uninterrupted C tract was unstable in the endometrial tumour. The
frequency of occurrence was 14% (seven out of 50). This particular
mtMSI has been reported in glioblastoma (Kirches et al, 2001) at a
frequency of 23% (four out of 17). These sequence variants when
in the mitochondrial haplotype have been considered as a
significant genetic predisposing factor for Type II diabetes
(Poulton, 1998). Indeed, we have recently observed (Liu et al,
2003) an elevated frequency of this haplotypic variant in patients
with endometrial carcinomas, suggesting that this may also be a
possible genetic predisposing factor for such human cancers.
The data presented here indicate a remarkably high frequency of
somatic mtDNA mutations in endometrial carcinomas. Although
the entire mitochondrial genome was not sequenced, this
particular stretch of mtDNA may be a hot spot region of somatic
mutations. The most abundant type of mutation observed in the
16S rRNA 12S rRNA D-loop
3229 16024
(4)( 1)(16)( 7)
Figure 1 Location of somatic mtDNA mutations detected in a particular
region (np from 16024–3229) of mitochondrial genome in endometrial
carcinomas. The locations of the mtDNA mutations are indicated by
arrows (positions not drawn exactly to scale). The arrows on top indicate
the positions of the seven point mutations and the 50-bp deletion (arrow
with a black circle at the tail). The arrows at the bottom indicate the
positions of the mtMSI. Numbers in parentheses indicate the number of
mtMSI detected out of 50 endometrial tumours. Gaps between genes
indicate the positions of tRNAs.
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mtDNA sequence variants representing the somatic mutations
occurring here, including point mutations and mtMSI variants, are
often found as germline polymorphisms in the human population,
it is worthwhile considering relevant issues including their possible
differential occurrence in various cancers, their proposed mechan-
isms of formation and their potential clinical significance.
Variation in the CA repeats was detected in only one (2%; one
out of 50) of the endometrial carcinoma samples. Instability of the
CA repeats was also found at a low frequency in ovarian (8%; two
out of 25) (Liu et al, 2001), gastric (19%; six out of 32) (Maximo
et al, 2001) and glioblastoma (6%; one out of 17) (Kirches et al,
2001) cancers. However, there is a significantly higher frequency of
the CA-repeat instability in breast cancer (42.5%; 17 out of 40)
(Richard et al, 2000). On the basis of these findings, we suggest
that somatic mtMSI occurs differentially in different tumours.
Malfunctions of mismatch repair genes have been associated
with nuclear MSI. However, to date, no mismatch repair genes
have been found responsible for the maintenance of mammalian
mitochondrial genome. The occurrence of high frequency (50%; 25
out of 50) of mtMSI in endometrial tumours indicates that DNA
repair in mitochondria is highly inefficient after malignant
transformation. The different frequencies of occurrence of
the mtMSI at the mononucleotide repeat at np 303–309 in
different tumour cell types suggests that deficits in mismatch
repair function in mitochondria may vary from one tumour to
another.
We detected a higher frequency of mtMSI than point mutations
in human endometrial carcinomas. This may be explained by the
different mechanisms of mtDNA alteration and/or repair in
different tissues during carcinogenesis. The occurrence of mtMSI
may derive mainly from erroneous replication, whereas point
mutations may be attributed to oxidative damage caused by
reactive oxygen species. In addition, a recent study (Longley et al,
2001) suggests that the homopolymorphic nucleotide tracts in
mtDNA are error-prone because of the low frameshift fidelity of
the DNA polymerase gamma that carries out the mtDNA
replication. Thus, mtMSI in endometrial carcinomas may be
mainly attributed to errors of replication. Moreover, there is
supportive evidence that there are cell-specific differences in the
repair of mtDNA damage (LeDoux and Wilson, 2001). The
differential occurrence of mtDNA mutations in various cancers
may be partly due to the prominence of different repair
mechanisms in different tumour cell types.
The active generation of new mtDNA variants by replication
error and inefficient repair is not the only explanation for the
appearance of mtMSI. Somatic mtDNA mutations accumulated in
tumours have been proposed to be the result of random genetic
drift (Coller et al, 2001; Jones et al, 2001). This means that the pre-
existing sequence variants, which could be present at a low level
among the heteroplasmic population of mtDNA in the progenitor
cells, could have outgrown, without any selection, other mtDNA
molecules after the hundreds or thousands of cell division cycles
leading to the clinically manifested tumour. Since many somatic
Table 1 Somatic mtDNA mutations found in human endometrial carcinomas
Code no. Gene Location Mutation type Wild type
a Normal Tumour
U9 D-loop 289–346 Deletion Normal length Normal length 50-bp deletion
G12 D-loop 152 Point mutation T T C
U34 D-loop 251 Point mutation G G G, A
U10 D-loop 294 Point mutation T T T, C
U27 12S RNA 650 Point mutation T T T, C
U59 12S RNA 817 Point mutation G G A
G29 12S RNA 879 Point mutation T T C
U44 16S RNA 3163 Point mutation G G A
U111 D-loop 514–523 mtMSI (CA)5 (CA)4 (CA)5
U24 12S RNA 956–960 mtMSI C5 C5 C4, C5
U32 12S RNA 956–960 mtMSI C5 C6 C6, C7
U120 12S RNA 956–960 mtMSI C5 C6 C7
U27 12S RNA 956–965 mtMSI CCCCCTCCCC C11, C12, C13, C14 C12, C13, C14
U10 D-loop 303–309 mtMSI C7 C8, C9 C8
U12 D-loop 303–309 mtMSI C7 C7, C8, C9 C8
U24 D-loop 303–309 mtMSI C7 C8, C9 C9, C10
U42 D-loop 303–309 mtMSI C7 C7, C8,C 9 C8, C9, C10
U44 D-loop 303–309 mtMSI C7 C7, C8, C9 C8, C9, C10, C11
U46 D-loop 303–309 mtMSI C7 C7, C8,C 9 C8, C9, C10,C 1 1
U52 D-loop 303–309 mtMSI C7 C7, C8,C 9 C8, C9, C10
U55 D-loop 303–309 mtMSI C7 C8, C9, C10 C9, C10
U56 D-loop 303–309 mtMSI C7 C8, C9 C8
U109 D-loop 303–309 mtMSI C7 C8, C9, C10, C11 C8,C 9
U120 D-loop 303–309 mtMSI C7 C8, C9,C 1 0 C 8
U125 D-loop 303–309 mtMSI C7 C8, C9, C10 C8,C 9
G24 D-loop 303–309 mtMSI C7 C7, C8, C9 C7, C8
G27 D-loop 303–309 mtMSI C7 C7 C7, C8
G35 D-loop 303–309 mtMSI C7 C9, C10 C9, C10, C11
G81 D-loop 303–309 mtMSI C7 C8, C9, C10 C9, C10, C11
U9 D-loop 16184–16193 mtMSI CCCCCTCCCC C13 C14
U25 D-loop 16184–16193 mtMSI CCCCCTCCCC C11 C12
U37 D-loop 16184–16193 mtMSI CCCCCTCCCC C12 C10, C11, C12
U44 D-loop 16184–16193 mtMSI CCCCCTCCCC C10 C10, C11, C12
U51 D-loop 16184–16193 mtMSI CCCCCTCCCC C11, C12, C13 C12, C13, C14
U58 D-loop 16184–16193 mtMSI CCCCCTCCCC C12 C11
G29 D-loop 16184–16193 mtMSI CCCCCTCCCC C7 C7, C8, C9, C10
Table entries in bold font indicate the predominant sequence variants in heteroplasmic mixtures.
aWild type indicates the nucleotide(s) in the Revised Cambridge reference
sequence (GenBank NC_001807).
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significance, for example, within the D-loop region, the presence of
somatic mtDNA mutations in tumours might not necessarily lead
to mitochondrial dysfunction. In this view, random genetic drift
could satisfactorily explain the occurrence of somatic mtDNA
mutations during carcinogenesis. A more detailed treatment of
these ideas has recently been presented by Chinnery et al (2002).
Nevertheless, it is still open to question whether there might be a
functional significance of the various mtMSI, point mutations and
deletions that are found in cancer tissues as homoplasmic somatic
mutations. It is conceivable that some mutations may be
functionally selected during neoplastic expansion. The possible
functional impact of somatic mtDNA mutations in cancer should
therefore be investigated, especially concerning those mutations
lying outside noncoding or nonconserved regions.
Finally, in a clinical context, the high frequency of mitochon-
drial genome instability, in combination with PCR-based assays of
high sensitivity, may be a potential new tool for endometrial
cancer detection (Parrella et al, 2001). Somatic mtMSI involving
the change in DNA length, even though the difference is only 1 or
2bp, can be readily detected by polyacrylamide gel electrophoresis
(Figure 3). In general, the bandshifts or band spreading observed
by gel electrophoresis after PCR amplification of tumour mtDNA
reflects the distribution of novel or multiple sequence variants in
the tumour compared to normal tissue from the same patient (see
legend to Figure 3 and relevant parts of Table 1). One particular
mutation, the mtMSI variant at the mononucleotide repeat at np
303–309 (Table l; see also foregoing discussion), because of its
frequent occurrence in various cancers, may be considered as a
potential new tool for early cancer detection. In this case, the
application of PCR coupled with gel electrophoresis lends itself to
rapid analysis of multiple samples.
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